DIAGNOS announces a 3-year partnership agreement with the University of Montreal Hospital Centre (CHUM) on the use of Artific...
January 19 2021 - 9:30AM
Diagnos Inc. ("DIAGNOS" or "Company") (TSX Venture Exchange: ADK)
(OTCQB: DGNOF), a leader in early detection of critical health
problems through the use of artificial intelligence (AI), announces
a three (3) year framework partnership agreement with the CHUM
(Center Hospitalier de l'Université de Montréal) on AI projects
applied to the early detection of various retinal diseases.
The various algorithms developed by DIAGNOS will
be used to analyze changes in retinal microcirculation and their
impacts on the prevention of complications of cardiovascular
disease.
This agreement also supports our project to
screen diabetic retinopathy with automatic detection assisted by
artificial intelligence, launched in June 2018. As soon as sanitary
conditions permit, the technological showcase will resume in the
endocrinology (diabetes) and ophthalmology clinics of the CHUM, in
order to complete its demonstration phase.
"We are pleased to be working with DIAGNOS to
bring innovation and excellence in care to patients. The evaluation
and refinement of DIAGNOS technology using artificial intelligence
in the early detection of certain diseases by our ophthalmology,
endocrinology and now cardiology teams contribute to improving the
quality and safety of the care provided to the population," said
Dr. Fabrice Brunet, President and CEO of
CHUM.
"DIAGNOS would like to thank the CHUM for its
support in demonstrating our technologies and also for the rigorous
work on the evaluation of the performance and safety of our CARA
platform. We have different projects that will allow us to develop
several innovations in AI with the analysis of the retina. These
new developments in early detection of diseases will have a low
cost and a non-invasive methodology for patients," said
André Larente, President of DIAGNOS.
About the University of Montreal
Hospital Centre (CHUM)The University of Montreal Hospital
Centre is an innovative hospital serving patients and the people of
Quebec. The CHUM takes an integrated approach to health and
population that is expressed in all aspects of its mission,
including care, teaching, research, management and innovation, as
well as in partnership with the patient and the citizen (SERGIP).
To achieve this goal of continuous improvement in population
health, management of patients' care and life trajectories was
implemented using data analyzed by artificial intelligence from
genetic and environmental information. In collaboration with other
stakeholders in the health and social services network, CHUM offers
the best specialized and subspecialized care based on
ever-increasing scientific knowledge. chumontreal.qc.ca
About DIAGNOSDIAGNOS is a
public Canadian company dedicated to early detection of health
problems based on its FLAIRE artificial intelligence (AI) platform.
The use of the FLAIRE platform allows for rapidly modifying and
developing applications such as CARA (Computer Assisted Retina
Analysis). CARA's artificial intelligence-based image enhancement
algorithms provide sharper, clearer and easier-to-analyze
traditional retinal images. CARA is a cost-effective tool for
real-time screening in a large number of patients. Cara has been
approved by a number of regulators, including Canada (Health
Canada), the United States (FDA), Mexico (COFEPRIS) and Europe
(EC).
More information is available on the
www.diagnos.com and www.sedar.com
This press release and/or reference documents
contain forward-looking information. We cannot guarantee that the
forward-looking information mentioned will prove to be accurate, as
there may be a significant discrepancy between actual results or
future events and those mentioned in this statement. DIAGNOS
disclaims any intention or obligation to publicly update or revise
any forward-looking information, whether as a result of new
information, future events or otherwise. The forward-looking
information contained in this press release is expressly covered by
this caution.
The TSX Venture Exchange and its regulatory
service provider (as a matter of policy under the TSX Venture
Exchange) assume no responsibility for the relevance or accuracy of
this press release.
For more information, please contact:
André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 x224
alarente@diagnos.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024